ObjectiveTo summarize and analyze the protocols of repetitive transcranial magnetic stimulation (rTMS) in the treatment of post-stroke lower limb dysfunction. MethodsLiterature about rTMS for lower limb dysfunction of patients post stroke were retrieved from Web of Science, PubMed, CNKI, and Wanfang Data from inception to August 17, 2022. The quality of the literature was evaluated with Physiotherapy Evidence Database (PEDro) scale. Literature quality, data extraction and scoping review were performed by two researchers. ResultsA total of 21 studies were included, in which 20 studies suggested that rTMS treatment could promote the recovery of lower limb motor function after stroke. One study showed negative result. rTMS interventions were reported safe, with no serious adverse reactions. There were great heterogeneity in the demographic and clinical information, study protocols, stimulation parameters, coil types, targets of stimulation, and motor-evoked potential measurement in the included studies. ConclusionThe future protocols of rTMS need to be combined with stroke stage and severity of injury. There is a demand for more real vs. sham rTMS studies, reporting similar designs with sufficient information, to achieve a significant level of evidence regarding the use of rTMS in post-stroke patients.

Objective To explore the relationship between carbohydrate sulfotransferase 6(CHST6)expression level and prognosis in glioma patients and construct prognosis model by using bioinformatics method.Methods To analyze the difference of CHST6 expression in glioma.The median CHST6 expression was divided into high and low expression groups.The prognostic differences between the groups were analyzed.The expression level of CHST6 and different clinical features were analyzed by Cox regression,and the prediction and improvement model was established,and the validity improvement was compared with the control model.Results A total of 1204 medical records were included in TCGA and CGGA databases.CHST6 was significantly up-regulated in glioma samples(TCGA vs.GTEx,Z= 2.457,P＜0.001;CGGA vs.GTEx,Z=4.800,P＜0.001),and was an independent prognostic factor for glioma together with age,WHO grade,IDH mutation status,and 1p19q co-deletion(Cox analysis β=0.02,SE=0.01,HR=1.02,95%CI:1.01～1.04,P=0.01;C-Index 0.885,95%CI:0.862～0.908),has higher predictive validity than the control model(Improved model vs.Control model:TCGA d=0.036±0.004,SE=0.002,P=0.007;CGGA d=0.087±0.004,SE=0.002,P=0.001).Conclusion The high expression of CHST6 may be a predictor of poor prognosis and abnormal immune function in glioma patients.